UXI1 Stock Chart & Stats
€1.48
€0.00(0.00%)
At close: 4:00 PM EDT
€1.48
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.11 - €9.58
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.26M
Enterprise Value€2.12
Total Cash (Recent Filing)€3.34M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.40
Shares Outstanding5,519,456
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-234.27
Revenue Forecast (FY)€87.15K
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthSustained double‑digit revenue expansion (TTM +104%) indicates improving commercial traction and product-market fit. Durable top-line momentum supports scaling economics, gives management room to leverage fixed costs, and is the primary path to narrowing large operating losses over the coming quarters.
Low Leverage / Improved EquityA debt‑free balance sheet and positive equity materially reduce solvency and refinancing risk. Improved capitalization versus prior negative equity provides durable financial flexibility to fund operations, support M&A or absorb shocks without immediate reliance on costly external debt markets.
Strategic Acquisition DiversificationPlanned Future NRG acquisition creates a regulated environmental platform combining fire safety, medical waste treatment and waste‑to‑energy services. This structural diversification links compliance‑driven niches, enabling bundled offerings and recurring revenue potential that can strengthen long‑term competitive positioning.
Bears Say
Ongoing Cash BurnPersistent negative operating and free cash flow implies continued funding needs and reliance on external financing until scale improves. Continued burn constrains reinvestment, raises dilution risk, and limits the company’s ability to sustain growth initiatives or absorb integration costs from M&A without new capital.
Large Operating LossesVery wide operating and net losses reflect a cost base far exceeding current revenue. Modest gross margins and steep negative margins mean profitability depends on substantial scale or structural cost reductions; without that, returns and shareholder value creation remain uncertain for the medium term.
Reliance On Equity FinancingFrequent equity raises and use of international private placements signal dependence on dilution to fund operations. Combined with preferred stock trading suspension and capital‑structure actions, this reliance can erode existing common equity value, complicate future raises, and increase investor scrutiny of financing strategy.
Bio Green Med Solution News
UXI1 FAQ
What was Bio Green Med Solution’s price range in the past 12 months?
Bio Green Med Solution lowest stock price was €1.11 and its highest was €9.58 in the past 12 months.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market cap is €4.26M.
When is Bio Green Med Solution’s upcoming earnings report date?
Bio Green Med Solution’s upcoming earnings report date is Aug 12, 2026 which is in 9 days.
How were Bio Green Med Solution’s earnings last quarter?
Bio Green Med Solution released its earnings results on May 14, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Bio Green Med Solution overvalued?
According to Wall Street analysts Bio Green Med Solution’s price is currently Overvalued.
Does Bio Green Med Solution pay dividends?
Bio Green Med Solution does not currently pay dividends.
What is Bio Green Med Solution’s EPS estimate?
Bio Green Med Solution’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio Green Med Solution have?
Bio Green Med Solution has 5,519,456 shares outstanding.
What happened to Bio Green Med Solution’s price movement after its last earnings report?
Bio Green Med Solution reported an EPS of -€0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bio Green Med Solution?
Currently, no hedge funds are holding shares in DE:UXI1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio Green Med Solution
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services. BGMS is committed to driving progress in biopharmaceutical research and developing cutting-edge fire safety solutions, striving to deliver enduring value to its investors.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Rein Therapeutics
―
Bluejay Diagnostics
―
Neuphoria Therapeutics
―